Seaport Therapeutics, Inc. (SPTX)
NASDAQ: SPTX · Real-Time Price · USD
22.39
+1.27 (6.01%)
Sep 22, 2026, 4:00 PM EDT - Market closed
Seaport Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The company presented its neuroscience-focused pipeline, highlighting the Glyph platform's ability to overcome oral bioavailability and liver toxicity issues. Lead programs GlyphAllo and GlyphAgo target depression and anxiety with promising clinical data and registration-enabling trials planned. The platform's versatility and AI-driven efficiencies position it for broader applications.
-
The company presented its neuropsychiatry-focused pipeline, highlighting the Glyph platform's ability to improve oral bioavailability and safety of known drugs. Key milestones include phase II-B and driving study data for GlyphAllo in 2026–2027 and phase II studies for GlyphAgo in 2028, with funding secured into 2029.